Risultati della ricerca - Jaume Capdevila

Raffina i risultati
  1. 1
    Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib

    Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib di Jaume Capdevila, Neda Stjepanovic

    Pubblicazione 2014
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  2. 2
    GEP–NETs UPDATE: Biotherapy for neuroendocrine tumours

    GEP–NETs UPDATE: Biotherapy for neuroendocrine tumours di Teresa Alonso‐Gordoa, Jaume Capdevila, Enrique Grande

    Pubblicazione 2014
    Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  3. 3
    Thyroid Cancer: Molecular Aspects and New Therapeutic Strategies

    Thyroid Cancer: Molecular Aspects and New Therapeutic Strategies di Enrique Grande, Juan J. Díez, Carles Zafón, Jaume Capdevila

    Pubblicazione 2012
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  4. 4
    Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer

    Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer di Anubha Gupta, Barbara Jarząb, Jaume Capdevila, Robert Shumaker, Ziad Hussein

    Pubblicazione 2016
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  5. 5
    What is the status of immunotherapy in thyroid neoplasms?

    What is the status of immunotherapy in thyroid neoplasms? di Alejandro García‐Álvarez, Jorge Hernando, Ana Carmona-Alonso, Jaume Capdevila

    Pubblicazione 2022
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  6. 6
    Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era

    Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era di Jaume Capdevila, Ahmad Awada, Dagmar Führer‐Sakel, Sophie Leboulleux, Patrick Pauwels

    Pubblicazione 2022
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  7. 7
    Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor Hypoxia

    Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor Hypoxia di Rodrigo A. Toledo, Camilo Jiménez, Gustavo Armaiz-Peña, Carlota Arenillas, Jaume Capdevila, Patricia L. M. Dahia

    Pubblicazione 2022
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  8. 8
    Cabozantinib for the treatment of solid tumors: a systematic review

    Cabozantinib for the treatment of solid tumors: a systematic review di Pablo Maroto, Camillo Porta, Jaume Capdevila, Andrea B. Apolo, Santiago Viteri, Cristina Rodríguez‐Antona, Lidia Martín, Daniel Castellano

    Pubblicazione 2022
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  9. 9
    Genomics Review of Selective <scp>RET</scp> Inhibitors Sensitivity in Thyroid Cancer Clinical Trials

    Genomics Review of Selective <scp>RET</scp> Inhibitors Sensitivity in Thyroid Cancer Clinical Trials di Sara Gil‐Bernabé, Lucía García‐DeLaFuente, Alejandro García‐Álvarez, Ginesa García‐Rostán, Jaume Capdevila, Jorge Hernando

    Pubblicazione 2025
    Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  10. 10
    Streptozotocin, 1982–2022: Forty Years from the FDA’s Approval to Treat Pancreatic Neuroendocrine Tumors

    Streptozotocin, 1982–2022: Forty Years from the FDA’s Approval to Treat Pancreatic Neuroendocrine Tumors di Jaume Capdevila, Michel Ducreux, Rocio García‐Carbonero, Enrique Grande, Þorvarður R. Hálfdánarson, Anne Couvelard, Salvatore Tafuto, Staffan Welin, Vicente Valentí, Ramón Salazar

    Pubblicazione 2022
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  11. 11
    Vandetanib in Advanced Medullary Thyroid Cancer: Review of Adverse Event Management Strategies

    Vandetanib in Advanced Medullary Thyroid Cancer: Review of Adverse Event Management Strategies di Enrique Grande, Michael C. Kreißl, Sébastiano Filetti, Kate Newbold, Walter Reinisch, Caroline Robert, Martin Schlumberger, Lærke Kjær Tolstrup, José Luís Zamorano, Jaume Capdevila

    Pubblicazione 2013
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  12. 12
    Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development

    Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in dev... di Rocio García‐Carbonero, Roberto García‐Figueiras, Alberto Carmona‐Bayonas, Isabel Sevilla, Àlex Teulé, María Quindós, Enrique Grande, Jaume Capdevila, Javier Aller, Javier Arbizu, Paula Jiménez‐Fonseca

    Pubblicazione 2015
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  13. 13
    Sorafenib in metastatic thyroid cancer

    Sorafenib in metastatic thyroid cancer di Jaume Capdevila, L. Iglesias, Irene Halperín, Ángel Segura, Javier Martínez‐Trufero, María Ángeles Vaz Salgado, J. Corral, Gabriel Obiols, Enrique Grande, Juan J. Grau, Josep Tabernero

    Pubblicazione 2012
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  14. 14
    Impact of Prior Chemotherapy Use on the Efficacy of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors

    Impact of Prior Chemotherapy Use on the Efficacy of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors di Catherine Lombard‐Bohas, James C. Yao, Timothy J. Hobday, Eric Van Cutsem, Edward M. Wolin, Ashok Panneerselvam, Sotirios Stergiopoulos, Manisha H. Shah, Jaume Capdevila, Rodney F. Pommier

    Pubblicazione 2014
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  15. 15
    Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results

    Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results di Marianne Pavel, Jarosław B. Ćwikła, Catherine Lombard‐Bohas, Ivan Borbath, Tahir Shah, Ulrich F. Pape, Jaume Capdevila, Francesco Panzuto, Xuan-Mai Truong Thanh, Aude Houchard, Philippe Ruszniewski

    Pubblicazione 2021
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  16. 16
    Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer

    Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer di Bruce Robinson, Martin Schlumberger, Lori J. Wirth, Corina E. Dutcus, James Song, Matthew H. Taylor, Sung‐Bae Kim, Monika K. Krzyzanowska, Jaume Capdevila, Steven I. Sherman, Makoto Tahara

    Pubblicazione 2016
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  17. 17
    Libretto-531: A Phase III Study of Selpercatinib in Multikinase Inhibitor-Naïve <i>RET</i> -Mutant Medullary Thyroid Cancer

    Libretto-531: A Phase III Study of Selpercatinib in Multikinase Inhibitor-Naïve <i>RET</i> -Mutant Medullary Thyroid Cancer di Lori J. Wirth, Marcia S. Brose, Rossella Elisei, Jaume Capdevila, Ana O. Hoff, Mimi I. Hu, Makoto Tahara, Bruce Robinson, Ming Gao, Xia Meng, Patricia Maeda, Eric J. Sherman

    Pubblicazione 2022
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  18. 18
    ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors

    ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors di Massimo Falconi, Barbro Eriksson, Gregory Kaltsas, Detlef K. Bartsch, Jaume Capdevila, Martyn Caplin, Beata Kos‐Kudła, Dik J. Kwekkeboom, Guido Rindi, Günter Klöppel, Nicholas S. Reed, Réza Kianmanesh, Robert T. Jensen

    Pubblicazione 2016
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  19. 19
    Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer

    Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer di Garazi Serna, Fiorella Ruíz‐Pace, Jorge Hernando, Lidia Alonso, Roberta Fasani, Stefania Landolfi, Raquel Comas, José Jiménez, Elena Élez, Susan Bullman, Josep Tabernero, Jaume Capdevila, Rodrigo Dienstmann, Paolo Nucíforo

    Pubblicazione 2020
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  20. 20
    A Phase I First-in-Human Pharmacokinetic and Pharmacodynamic Study of Serdemetan in Patients with Advanced Solid Tumors

    A Phase I First-in-Human Pharmacokinetic and Pharmacodynamic Study of Serdemetan in Patients with Advanced Solid Tumors di Josep Tabernero, Luc Dirix, Patrick Schöffski, Andrés Cervantes, José A. López-Martín, Jaume Capdevila, Ludy van Beijsterveldt, Suso Platero, Brett M. Hall, Zhilong Yuan, R.E. Knoblauch, Sen Hong Zhuang

    Pubblicazione 2011
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:

Strumenti per la ricerca: